<DOC>
	<DOCNO>NCT01600807</DOCNO>
	<brief_summary>OSI-906 new drug may stop cancer cell grow abnormally . This drug use research study information suggest OSI-906 may help block cell receptor involve tumor growth . Gemcitabine erlotinib use standard treatment pancreatic cancer . In research study , investigator look high dose OSI-906 give safely combination gemcitabine erlotinib . This dose give together gemcitabine erlotinib group patient pancreatic cancer .</brief_summary>
	<brief_title>OSI-906 With Gemcitabine Erlotinib Metastatic Ductal Adenocarcinoma Pancreas</brief_title>
	<detailed_description>This study conduct two part : phase I study phase II study . In instance , treatment cycle 28 day ( 4 week ) . Subjects take OSI-906 mouth , twice day , every day . Subjects receive gemcitabine IV clinic 30 minute day 1 , 8 15 28-day cycle . Subjects take erlotinib mouth , day , every day . At every visit subject physical exam blood test . An EKG do day 1 , 8 15 cycle 1 day 1 subsequent cycle . A CT scan do every 2 cycle ( 8 week ) . Subjects complete daily drug diary perform glucose monitoring ( finger stick ) daily home .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Metastatic pancreatic ductal adenocarcinoma Measurable disease Life expectancy &gt; 12 week Normal organ marrow function Fasting blood glucose &lt; /= 150 mg/dL Able swallow pill Prior chemotherapy radiotherapy treatment pancreatic cancer Receiving experimental agent Known brain metastasis History allergic reaction attribute compound similar chemical biologic composition gemcitabine , erlotinib , OSI906 Impairment gastrointestinal function gastrointestinal disease ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea ) Use enzymeinducing antiepileptic drug Diabetes mellitus require use exogenous insulin glucose control Major surgery within 4 week start study treatment Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Use strong moderate CYP1A2 inhibitors/inducers Pregnant breast feed History different malignancy unless diseasefree least 3 year HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Metastatic</keyword>
	<keyword>Pancreas</keyword>
	<keyword>Cancer</keyword>
	<keyword>Adenocarcinoma</keyword>
</DOC>